利血平和α-甲基多巴治疗迟发性运动障碍
Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia.
作者信息
Huang C C, Wang R I, Hasegawa A, Alverno L
出版信息
Psychopharmacology (Berl). 1981;73(4):359-62. doi: 10.1007/BF00426466.
PMID:6789358
Abstract
Thirty inpatients with evidence of tardive dyskinesia secondary to antipsychotic medications participated in this double-blind, controlled, randomized study comparing reserpine, alpha-methyldopa and placebo. Reserpine at doses of 0.75--1.5 mg daily, or alpha-methyldopa at doses of 750--1,500 mg daily, produced a statistically significant improvement in tardive dyskinesia symptomatology compared to the results obtained with placebo.
摘要
30名有抗精神病药物所致迟发性运动障碍证据的住院患者参与了这项双盲、对照、随机研究，该研究比较了利血平、α-甲基多巴和安慰剂。与安慰剂相比，每日剂量为0.75--1.5毫克的利血平或每日剂量为750--1500毫克的α-甲基多巴在迟发性运动障碍症状学方面产生了具有统计学意义的改善。
Zotero 插件